XML 130 R114.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Related Party Transactions - Additional Information (Details) - USD ($) | 1 Months Ended | 12 Months Ended | 49 Months Ended
--- | --- | --- | ---
Dec. 31, 2016 | Oct. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Nov. 30, 2015 | Jul. 31, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Feb. 28, 2015
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued as compensation for services |  |  |  |  |  |  |  |  |  | $ 10,777,000 | $ 2,169,000 | $ 486,000 |
Fair value of assets | $ 335,307,000 |  |  |  |  |  |  |  |  | 335,307,000 | 291,762,000 |  |
Other nonoperating income |  |  |  |  |  |  |  |  |  | 1,700,000 | 1,314,000 | (168,000) |
Purchases of equity securities and warrants |  |  |  |  |  |  |  |  |  | 2,308,000 | 17,080,000 | 19,496,000 |
Third Security, LLC |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for services |  |  |  |  |  |  |  |  |  | $ 309,000 | $ 428,000 | $ 291,000 |
Services agreement, term |  | 2 months |  |  | 1 year |  |  |  |  |  |  |  |
Shares issued as compensation for services, shares |  |  |  |  |  |  |  |  |  | 337,163 | 48,678 |  |
Shares issued as compensation for services |  |  |  |  |  |  |  |  |  | $ 8,571,000 | $ 1,375,000 |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock purchased from collaborative partners, value |  |  |  |  |  |  |  |  |  |  |  |  | $ 43,582,000
Oragenics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock purchased from collaborative partners, shares |  |  |  | 2,261,419 |  |  |  |  |  |  |  |  |
Price per share of common shares (in usd per share) |  |  |  | $ 0.52 |  |  |  |  |  |  |  |  |
Fibrocell Science, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire convertible notes and warrants |  |  | $ 2,604,000 |  |  |  |  |  |  |  |  |  |
Common stock purchased from collaborative partners, shares |  |  |  |  |  | 375,868 |  |  |  |  |  |  |
Price per share of common shares (in usd per share) |  |  |  |  |  | $ 5.80 |  |  |  |  |  |  |
AmpliPhi Biosciences Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock purchased from collaborative partners, shares |  |  |  |  |  |  | 278,788 |  |  |  |  |  |
Warrants purchased from collaborative partners, shares |  |  |  |  |  |  | 69,696 |  |  |  |  |  |
Purchases of equity securities and warrants |  |  |  |  |  |  | $ 2,300,000 |  |  |  |  |  |
Histogenics Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock purchased from collaborative partners, shares |  |  |  |  |  |  |  | 1,772,364 |  |  |  |  |
Price per share of common shares (in usd per share) |  |  |  |  |  |  |  |  |  |  | $ 11.00 |  |
Note receivable interest rate |  |  |  |  |  |  |  |  | 6.00% |  |  |  |
Histogenics Corporation | Upfront and milestone payments | Upfront |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value of convertible promissory note |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |
Harvest Intrexon Enterprise Fund I, LP |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Other nonoperating income |  |  |  |  |  |  |  |  |  | 2,483,000 | $ 1,349,000 |  |
Common Stock | Third Security, LLC |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Expense for services |  |  |  |  | $ 800,000 |  |  |  |  |  |  |  |
Warrants | AmpliPhi Biosciences Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Purchases of equity securities and warrants |  |  |  |  |  |  | 321,000 |  |  |  |  |  |
Common Stock | AmpliPhi Biosciences Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Purchases of equity securities and warrants |  |  |  |  |  |  | $ 1,979,000 |  |  |  |  |  |
Other assets | Convertible note and warrants | Fibrocell Science, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of assets | $ 1,642,000 |  |  |  |  |  |  |  |  | $ 1,642,000 |  |  |
Third Security, LLC | Chief Executive Officer |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest | 100.00% |  |  |  |  |  |  |  |  | 100.00% |  |  |
AmpliPhi Biosciences Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Realized investment gain (loss) | $ (4,098,000) |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (expense) related to nonoperating activities, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investments classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. + References No definition available. + Details
Name: | us-gaap_ProfessionalAndContractServicesExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.3(a)) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 325 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6485959&loc=d3e22529-158502 + Details
Name: | us-gaap_RealizedInvestmentGainsLosses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest rate per annum of the note receivable. + References No definition available. + Details
Name: | xon_NoteReceivableInterestRate
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money and/or common stock at a future date as well as warrants to purchase additional common shares of the maker of the note. + References No definition available. + Details
Name: | xon_PaymentstoAcquireConvertibleNotesandWarrants
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in a related party. + References No definition available. + Details
Name: | xon_RelatedPartyOwnershipInterest
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Initial term of a services agreement. + References No definition available. + Details
Name: | xon_ServicesAgreementTerm
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of common stock purchased from collaborator + References No definition available. + Details
Name: | xon_SharesPurchasedFromCollaborativePartners
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of common stock purchased from collaborator + References No definition available. + Details
Name: | xon_SharesPurchasedFromCollaborativePartnersValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price per share of collaborator's common stock purchased + References No definition available. + Details
Name: | xon_SharesPurchasedPricePerShare
Namespace Prefix: | xon_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants purchased from collaborator + References No definition available. + Details
Name: | xon_WarrantsPurchasedFromCollaborativePartners
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ThirdSecurityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_AmpliPhiBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_HistogenicsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_UpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=xon_HarvestIntrexonEnterpriseFundILPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=xon_ConvertibleNoteandWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xon_ThirdSecurityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xon_AmpliPhiBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |